MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 47 Publications

10 Customer Reviews

  • MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

    HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  • HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

     

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

  • JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

    LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

  • Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NX\GdGhRTnWwY4Tpc44hSXO|YYm= MX:yOUDPxE1? NHHZTJJFVVOR M4XNWmlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN NXLCV2RUOjR4OUe0PVY>
HL-60 NWDRSYpbS3m2b4TvfIlkKEG|c3H5 Mmi4OFAh|ryP MXO0PEBp NX3HU4pGTE2VTx?= MVXJR|UxRDFyIN88US=> M3zUNlI1Pjl5NEm2
SMMC-7721 NGPDZlZEgXSxdH;4bYMhSXO|YYm= NGPCXVA1OCEQvF2= NX3zSJQ5PDhiaB?= M4fY[GROW09? MnG4TWM2OD15LkGg{txO M2HDZ|I1Pjl5NEm2
A-549 MXPDfZRwfG:6aXOgRZN{[Xl? NEHJOpA1OCEQvF2= NUfqd2xuPDhiaB?= NWDkU2FwTE2VTx?= MoPyTWM2ODxzMDFOwG0> MmjmNlQ3QTd2OU[=
MCF-7 NIfTS2pEgXSxdH;4bYMhSXO|YYm= MWG0NEDPxE1? NF\KbVU1QCCq MlrCSG1UVw>? NWjLNmh{UUN3ME23MlMh|ryP NVvoSYZoOjR4OUe0PVY>
SW-480 MULDfZRwfG:6aXOgRZN{[Xl? MmT1OFAh|ryP NGjzVWk1QCCq MnnaSG1UVw>? NGPHbWlKSzVyPUSg{txO NWK1W|JNOjR4OUe0PVY>
NCI-H929 MVTDfZRwfG:6aXOgRZN{[Xl? NHnzNYkyKM7:TR?= MUW3NkBp M1P1WGROW09? MVrJR|UxRTBwMUeg{txO NFz3bYozPDZ{NUC4PC=>
293T MkjjR5l1d3SxeHnjJGF{e2G7 NYHPZ2J3OTBizszN MWG3NkBp MkTBSG1UVw>? M16zdGlEPTB:MjFOwG0> NEjudY0zPDZ{NUC4PC=>
293T NVHpXoV7TnWwY4Tpc44hSXO|YYm= M3m0[lExKM7:TR?= MoC0NlQhcA>? M1;HbGROW09? NF\TS2JOd2SncnH0[Yx6KGmwZIXj[ZMhcGWjdD3zbI9kcyBi NYfBfWI6OjR4MkWwPFg>
HeLa MV;LbY5ie2ViQYPzZZk> MkjlNVAh|ryP NHrDTpcyKGh? NHXtNmpFVVOR MYXJcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5 Ml\HNlQ{OjF6M{O=
MDA-MB-231 NVn6RWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rJdVEh|ryP Mn7IO|IhcA>? M{PQWmROW09? M1fTT2lEPTB;MD6xPEDPxE1? M3;Lb|I1OTV|MkC2
MCF-7 M4TtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FNUDPxE1? NGXhW4o4OiCq MWPEUXNQ NV\icGx7UUN3ME2wMlE{KM7:TR?= MlXINlQyPTN{ME[=
MCF10A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xJO69VQ>? NIKyWXo4OiCq NYnBc4tqTE2VTx?= MVvJR|UxRTBwMkmg{txO MnL3NlQyPTN{ME[=
HEK-293 Mn35T4lv[XOnIFHzd4F6 M{LONVIh[W6mIEKwJO69VQ>? NIexNWEzKGh? MlzmSG1UVw>? MmXuTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1i MWCyN|U1ODd7MB?=
Calu6 NY\W[ZdjTnWwY4Tpc44hSXO|YYm= NULoSXdQOTBizszN NUTpc|RxOThiaB?= MW\EUXNQ NV\zcnRNW2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I> NVHL[FRUOjN3ME[0PFY>
IFN-gamma-induced RAW264.7 M3rse2Z2dmO2aX;uJGF{e2G7 NGjzWFFFVVOR NILJcpZKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5yN{eg{txO MmnxNlIzPzd{N{e=
IPC227F MUTDfZRwfG:6aXOgRZN{[Xl? NYjqW41qOSEQvF2= NWK1cndVPDhiaB?= NYDH[nUxTE2VTx?= NEnFWGRKSzVyPUCuNFc4KM7:TR?= NWX3eohwOjF7MkS1Nlg>
Hepa-1c1c7 NGnBTFJHfW6ldHnvckBCe3OjeR?= NHvXRmYzPSEQvF2= NXLMPWNJPiCq M{f2UWROW09? NUXsPFZZUW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>? NV7KV49VOjB|OUK1OFQ>
COS-7 Moj4R5l1d3SxeHnjJGF{e2G7 NF7KcYEyOCEQvF2= MmXtSG1UVw>? M3rqd2lEPTB:MUCg{txO NGLMUYQyQDB6OEC5Oy=>
HuH-7 M2DmcGN6fG:2b4jpZ{BCe3OjeR?= Ml;HNVAh|ryP M1;HUWROW09? M3[yfGlEPTB:MUCg{txO NVjEU3h3OThyOEiwPVc>
OCI-Ly3 Mn21SpVv[3Srb36gRZN{[Xl? MVGxNEDPxE4EoB?= NIHOdI41KGh? MkTuSG1UVw>? M1PY[mlv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP M3v2[VE5ODJ2MUGz
A2780 cDDP M3XQTmFxd3C2b4Ppd{BCe3OjeR?= NVHnUmtPOjRiaB?= MYDEUXNQ MXnJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44> NIDNOJMyPzZ6NECxPC=>
LPS-stimulated RAW264.7 cells MYfGeY5kfGmxbjDBd5NigQ>? NX;GVII5TE2VTx?= NGjMfZZKdmirYnn0d{BPTi2tYYDwZWIhTE6DIHLpcoRqdmd? MmTINVc1ODd{N{e=
PC12 NXP6[pJ5TnWwY4Tpc44hSXO|YYm= MmrsNVAxKM7:TdMg M{TpfVI1KGh? MVzEUXNQ M3LaTmlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NUmwU2FMOTdzNUi0OVQ>
PC3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjyTYgzOCEQvF2= NUfrT|FuPDhiaB?= NX7vSpFjTE2VTx?= M1HR[WlEPTB;MD62JO69VQ>? NFnTNnMyPjZ6NkWzOy=>
LP-1 NH3hZ4ZCeG:ydH;zbZMhSXO|YYm= Mon3N|AxKG6P MlryNlQhcA>? NYHQPY1yTE2VTx?= M2rofmlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwY4LlZZNqdmdiY3zlZZZm\CCSQWLQJIxmfmWuIHHu[EBz\WS3Y3nu[{BO[2xvMTDwdo91\WmwIHzleoVt NUDM[3VPOTV7NUi1PFk>
ES6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEGzNFYh|ryP NEi2bG1USU6JRWK=
A101D MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HkeWlEPTB;MD6wN|I4QSEQvF2= NWrqVo1EW0GQR1XS
OCUB-M MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm3TWM2OD1yLkCzO|M4KM7:TR?= MXfTRW5ITVJ?
LB2518-MEL NULLe3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe4VXVKSzVyPUCuNFM4PiEQvF2= NILlbFdUSU6JRWK=
SH-4 NX;GTmx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO3TWZwUUN3ME2wMlA1OzFizszN NVXzSFMzW0GQR1XS
KNS-42 NUi3SFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMES0OFEh|ryP Mn63V2FPT0WU
DSH1 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH62T5BKSzVyPUCuNFUzQDlizszN M3zxbXNCVkeHUh?=
NTERA-S-cl-D1 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm2RZhQUUN3ME2wMlA2Pzd{IN88US=> NHy5OYVUSU6JRWK=
D-542MG NYP1ZY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP1dYdpUUN3ME2wMlA2QTV5IN88US=> MXnTRW5ITVJ?
KS-1 M125emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwME[0OVgh|ryP NXHUeG5zW0GQR1XS
BL-41 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHyUolKSzVyPUCuNFY6PDdizszN Mof1V2FPT0WU
LXF-289 NFjVfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfLbHNKSzVyPUCuNFcxPjZizszN MUTTRW5ITVJ?
D-247MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LlOmlEPTB;MD6wO|IxQSEQvF2= NUPmd5FQW0GQR1XS
MMAC-SF NGTqRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITiNo1KSzVyPUCuNFczPjhizszN MVfTRW5ITVJ?
CP66-MEL MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrvR3lKSzVyPUCuNFc2KM7:TR?= Ml70V2FPT0WU
LB771-HNC MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEiwN|Yh|ryP NULSfnZVW0GQR1XS
no-10 M3jMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XhV2lEPTB;MD6wPFkxQSEQvF2= MVPTRW5ITVJ?
A388 NGi3OmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEmwOlUh|ryP NIPYUJFUSU6JRWK=
OPM-2 NFLpU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zJVWlEPTB;MD6xNFQ4PCEQvF2= M4DRVHNCVkeHUh?=
OVCAR-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPpTWM2OD1yLkGwPVM5KM7:TR?= NWnqSWlHW0GQR1XS
HOP-62 NILP[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjFXpd3UUN3ME2wMlExQTR7IN88US=> MVPTRW5ITVJ?
ML-2 NXm1Zph1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMUG4NFYh|ryP M3X3b3NCVkeHUh?=
UACC-257 NGfpW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q1cmlEPTB;MD6xNVkzPyEQvF2= NVTDRpdEW0GQR1XS
NEC8 NYDCdFhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\rTWM2OD1yLkGxPVk2KM7:TR?= M2fYcnNCVkeHUh?=
ONS-76 NILuVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTtTWM2OD1yLkGyPVM2KM7:TR?= NFfjbI9USU6JRWK=
KE-37 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSyZ2RKSzVyPUCuNVMzPzhizszN M17SbXNCVkeHUh?=
HT-144 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTXcWFKSzVyPUCuNVM5QTVizszN MYjTRW5ITVJ?
LB2241-RCC NYWy[3F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfITWM2OD1yLkG0NlQ4KM7:TR?= NVjEPZlvW0GQR1XS
TE-5 M3npR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3wcmVKSzVyPUCuNVQzPzhizszN Mlz3V2FPT0WU
KINGS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHke2tKSzVyPUCuNVQ4QSEQvF2= NHmxcnVUSU6JRWK=
NCI-H69 M1\rU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLiTWM2OD1yLkG1NVQyKM7:TR?= NFLQUpVUSU6JRWK=
CAS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DhNmlEPTB;MD6xOVQ5OiEQvF2= M{nRUXNCVkeHUh?=
D-263MG MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPxTWM2OD1yLkG2NFA3KM7:TR?= Mk\RV2FPT0WU
A253 NH7KdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMU[xNlgh|ryP M3eyb3NCVkeHUh?=
PF-382 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMU[3NFYh|ryP NVm0fIpsW0GQR1XS
CESS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMUewOkDPxE1? MUDTRW5ITVJ?
MZ2-MEL NHryNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HlbGlEPTB;MD6xO|U2QSEQvF2= MmrrV2FPT0WU
HEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3PTWh2UUN3ME2wMlE5PTF5IN88US=> NGnlT|lUSU6JRWK=
D-392MG MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHMfGJFUUN3ME2wMlE6OTF3IN88US=> MUTTRW5ITVJ?
SK-LMS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMUmzNFMh|ryP MkDmV2FPT0WU
GI-ME-N NF\MWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLOTppKSzVyPUCuNVk{ODZizszN Mke4V2FPT0WU
LB831-BLC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz2TWM2OD1yLkG5N|Qh|ryP NITDS2RUSU6JRWK=
DU-4475 NWjERYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMUm2OVgh|ryP M1rB[3NCVkeHUh?=
IST-SL1 NHjvV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH2TWNKSzVyPUCuNlAxQTRizszN NEXzSnFUSU6JRWK=
GAK MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T4VWlEPTB;MD6yNFU{PCEQvF2= NG\nR4lUSU6JRWK=
EW-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jOTWlEPTB;MD6yNVA1PyEQvF2= MoPjV2FPT0WU
LAMA-84 NHH3UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPLNI9sUUN3ME2wMlIyQDVzIN88US=> M2fIXXNCVkeHUh?=
SK-UT-1 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPFTWk{UUN3ME2wMlIzODR7IN88US=> M2r4d3NCVkeHUh?=
VA-ES-BJ NWHRdIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXLTWM2OD1yLkKyNlU4KM7:TR?= NFLVW29USU6JRWK=
ACN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DIXmlEPTB;MD6yNlY{QCEQvF2= MkPEV2FPT0WU
SK-PN-DW MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfzTWM2OD1yLkKzNVkh|ryP MnLnV2FPT0WU
HD-MY-Z NH\NXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjNTWM2OD1yLkKzN|A{KM7:TR?= MkHjV2FPT0WU
LB373-MEL-D MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHuTWM2OD1yLkK0NVk5KM7:TR?= MVTTRW5ITVJ?
COLO-829 NYTzcmpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjjXWdtUUN3ME2wMlI1OjV5IN88US=> Ml[3V2FPT0WU
ES8 M4rEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPlZld7UUN3ME2wMlI1PzZ|IN88US=> MoPuV2FPT0WU
RXF393 NHTZZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTvTWM2OD1yLkK1NFE2KM7:TR?= NHXIfnRUSU6JRWK=
TK10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMkW0N|Uh|ryP M3voNnNCVkeHUh?=
LOUCY NV6xT4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\tT2lEPTB;MD6yOVQ2PiEQvF2= MofEV2FPT0WU
MZ7-mel NF3Pe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTe5BKSzVyPUCuNlY{PzRizszN MWjTRW5ITVJ?
CP67-MEL NX7wZ5E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfYc29KSzVyPUCuNlY4OyEQvF2= NVTkblhbW0GQR1XS
C2BBe1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj6bFZKSzVyPUCuNlc6ODdizszN MkXBV2FPT0WU
K052 NWrOcoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDDTWM2OD1yLkK4PVkh|ryP MnvpV2FPT0WU
MOLT-16 M2P3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmxTWM2OD1yLkK5OVI1KM7:TR?= M2rkN3NCVkeHUh?=
KNS-81-FD M2XWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwM{CzNlMh|ryP M4XYeXNCVkeHUh?=
CMK NEToXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXZTWM2OD1yLkOxNVIh|ryP NULTUmx5W0GQR1XS
LAN-6 M4HF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H2b2lEPTB;MD6zNVMh|ryP Mnf0V2FPT0WU
KLE NFHjPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwM{GzNFYh|ryP M3fTPHNCVkeHUh?=
NCCIT NUXjU45zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwM{G3PFMh|ryP MmXEV2FPT0WU
HH MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{K4PVch|ryP Ml\JV2FPT0WU
TE-8 NIq1[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nrRmlEPTB;MD6zOFI4QSEQvF2= MWrTRW5ITVJ?
GDM-1 NUnLTXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe1UYlOUUN3ME2wMlM2OTB2IN88US=> M{H3WXNCVkeHUh?=
NCI-H747 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;meJJKSzVyPUCuN|cyODNizszN M{LFRXNCVkeHUh?=
NCI-H1092 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDyU3VSUUN3ME2wMlM5QDR2IN88US=> NV\lS|Z4W0GQR1XS
8-MG-BA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULaUGFDUUN3ME2wMlM6QDN5IN88US=> NFrD[G5USU6JRWK=
NB17 NH;YTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnvTWM2OD1yLkSyPVch|ryP MkG1V2FPT0WU
LC4-1 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNEO2NFch|ryP NE\kZpZUSU6JRWK=
TE-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17jS2lEPTB;MD60OVEyQSEQvF2= NGDZXWNUSU6JRWK=
KALS-1 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TTPGlEPTB;MD60OlU5PCEQvF2= NXH5NphJW0GQR1XS
CCRF-CEM MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzYTnZGUUN3ME2wMlQ4Pjd2IN88US=> MYXTRW5ITVJ?
OS-RC-2 NF;6SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwNEe5O|Ih|ryP NX;nO4hlW0GQR1XS
A704 NVS2WnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLUXZdKSzVyPUCuOFg3QTJizszN MULTRW5ITVJ?
BB49-HNC M{eyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjHTWM2OD1yLkS5NFk3KM7:TR?= NXPHXGY6W0GQR1XS
EVSA-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ae2lEPTB;MD60PVkyOSEQvF2= M1n5TnNCVkeHUh?=
Mo-T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXEUplKSzVyPUCuOVE4PjJizszN MXXTRW5ITVJ?
MONO-MAC-6 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Luc2lEPTB;MD61N|YyOSEQvF2= MWDTRW5ITVJ?
BB65-RCC NGDRfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nRdGlEPTB;MD61OlgyOSEQvF2= Mm[wV2FPT0WU
NCI-H1882 NUTDSoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH31ZXRKSzVyPUCuOVkxOzZizszN NVuzRlRSW0GQR1XS
TE-9 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNkGwN|Mh|ryP NIrvdHRUSU6JRWK=
NCI-H2126 NUnNd|ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\N[VFKSzVyPUCuOlI3PjlizszN MX;TRW5ITVJ?
SF268 M1jySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHSWmJKSzVyPUCuOlU3PDFizszN M4\R[HNCVkeHUh?=
SW872 NW\IO|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnflTWM2OD1yLk[1O|I6KM7:TR?= MUfTRW5ITVJ?
LS-513 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn0TlUzUUN3ME2wMlY3PzVzIN88US=> NEfuZ5ZUSU6JRWK=
NCI-H1355 NXm4fVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK4TWM2OD1yLk[4OlE6KM7:TR?= NE\0OHdUSU6JRWK=
BL-70 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LhUmlEPTB;MD62PVM5QCEQvF2= MUDTRW5ITVJ?
NCI-SNU-5 NUDXWpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOwT3dKSzVyPUCuOlk2PDVizszN NF\BU5BUSU6JRWK=
SNU-C2B M2TnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwN{C3N|kh|ryP NYfnN4lJW0GQR1XS
GB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rHNWlEPTB;MD63NlEzPCEQvF2= NYrMZ2prW0GQR1XS
CTB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnWVGJKSzVyPUCuO|c6PTVizszN MnnMV2FPT0WU
Becker NUj6[|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf5dXFKSzVyPUCuO|k3OjFizszN MYfTRW5ITVJ?
KM12 M2O5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\HTHlKSzVyPUCuPFU1PjZizszN NEHMfW5USU6JRWK=
ES7 NVfYeJk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf3O45KSzVyPUCuPFk3PSEQvF2= NYq0Z4JoW0GQR1XS
COLO-684 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;XdlVKSzVyPUCuPVA3PThizszN M3nuTnNCVkeHUh?=
HCC2998 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwOUO4OVQh|ryP MmTHV2FPT0WU
TE-10 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnHXVFXUUN3ME2wMlk3PDNizszN MXTTRW5ITVJ?
SF126 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;2TWM2OD1yLkm4PVcyKM7:TR?= MlrOV2FPT0WU
EKVX MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDXeFY{UUN3ME2xMlA{PDR{IN88US=> NUHI[HZpW0GQR1XS
KARPAS-45 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjtO41SUUN3ME2xMlA1ODF4IN88US=> MYHTRW5ITVJ?
KGN Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwMEWwOFUh|ryP MXPTRW5ITVJ?
ES1 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PxTWlEPTB;MT6wO|kzOSEQvF2= MXrTRW5ITVJ?
L-540 NUXhPYljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHZNmFLUUN3ME2xMlEyQDN7IN88US=> MkLvV2FPT0WU
KURAMOCHI M4\JPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi4OYpKSzVyPUGuNVI{PzRizszN M2D2NHNCVkeHUh?=
LU-65 NVrYN3JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMUK3OVMh|ryP M3zQR3NCVkeHUh?=
MFH-ino MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjofWhKSzVyPUGuNVc2ODFizszN NUm1R4Y1W0GQR1XS
NCI-H23 M3HURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwMkC0NUDPxE1? MknxV2FPT0WU
IA-LM MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH23V21KSzVyPUGuNlQyOTZizszN NYjq[oNTW0GQR1XS
PSN1 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;PUWlEPTB;MT6yO|AyPiEQvF2= MnLwV2FPT0WU
NCI-H719 NFXEU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S5R2lEPTB;MT6yO|QyOSEQvF2= MWLTRW5ITVJ?
SW684 M2LEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XIXWlEPTB;MT6yPFY2QSEQvF2= M2CyeXNCVkeHUh?=
HCE-4 NFfqcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD1zLkOwNlIyKM7:TR?= NWDWb2tYW0GQR1XS
EW-16 M16z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TofWlEPTB;MT6zNVM1PyEQvF2= M3PFZ3NCVkeHUh?=
NCI-H128 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XrZ2lEPTB;MT6zOVgyPCEQvF2= M3zheXNCVkeHUh?=
HC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4npc2lEPTB;MT6zPFE4KM7:TR?= MWPTRW5ITVJ?
IST-MES1 NGnFPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XE[GlEPTB;MT60NFIxQCEQvF2= M1LwPXNCVkeHUh?=
Raji NGTycpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDUW5NiUUN3ME2xMlQyQDVizszN MkL2V2FPT0WU
DMS-114 NGT4UWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwNES1N|kh|ryP MVvTRW5ITVJ?
GI-1 NFPoe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXrV5pKSzVyPUGuOFcyOzFizszN M4XRT3NCVkeHUh?=
NCI-H2081 NI\BWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HQSGlEPTB;MT61OVE6PiEQvF2= MXLTRW5ITVJ?
LC-1F Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7Oco9KSzVyPUGuOVUyQThizszN NHr3NFJUSU6JRWK=
NCI-H2227 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwNkG1OlEh|ryP MnrMV2FPT0WU
D-502MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPOTWM2OD1zLk[3NlEyKM7:TR?= M2TwXHNCVkeHUh?=
NCI-H2141 NViyc2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfzd5lJUUN3ME2xMlY4OzF5IN88US=> MVnTRW5ITVJ?
LS-411N NHS2[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrXNFRzUUN3ME2xMlY6QDB5IN88US=> MmfOV2FPT0WU
SU-DHL-1 NVfadoFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwN{GyPFEh|ryP MmnSV2FPT0WU
BB30-HNC NW\iOWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfibXJKSzVyPUGuO|I3QDVizszN NELSV2tUSU6JRWK=
TE-15 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfh[3hKSzVyPUGuPVI{PzNizszN NX\tTopjW0GQR1XS
JVM-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vEV2lEPTB;MT65N|kxPCEQvF2= MVPTRW5ITVJ?
IST-SL2 M{\q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDGZ4JCUUN3ME2yMlAyOjV{IN88US=> MW\TRW5ITVJ?
EW-18 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\QTWM2OD1{LkCyN|M4KM7:TR?= MlrsV2FPT0WU
DJM-1 NH;pRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwMEK1OVIh|ryP MlGxV2FPT0WU
no-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwMEOxNFQh|ryP NXi5VnJvW0GQR1XS
QIMR-WIL MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNV2lEPTB;Mj6xOlc3OiEQvF2= MUfTRW5ITVJ?
MC-CAR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJwMkK5OUDPxE1? MXLTRW5ITVJ?
KM-H2 M3\ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPPOGRIUUN3ME2yMlI6ODR|IN88US=> MljaV2FPT0WU
ECC12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwM{e5OEDPxE1? M37Gb3NCVkeHUh?=
HCE-T NVLKcmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\pNItVUUN3ME2yMlQ1QDh|IN88US=> NIGxN2dUSU6JRWK=
MFM-223 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH4epJKUUN3ME2yMlUxQDdzIN88US=> MXfTRW5ITVJ?
SW982 NVXhOY5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPCTWM2OD1{LkWxOFgh|ryP MkewV2FPT0WU
KG-1 NFzse4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr6VVhQUUN3ME2yMlg5PzlzIN88US=> M{n4ZnNCVkeHUh?=
ES4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P1SGlEPTB;Mz6wOlEyOSEQvF2= NH;kV4pUSU6JRWK=
SCC-3 NFLxWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrZVWlKSzVyPUOuNVA5PDhizszN Mon2V2FPT0WU
RH-1 NWfjcJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfXNY9KSzVyPUOuN|g4PDhizszN NX35e29XW0GQR1XS
NCI-H748 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrE[FIyUUN3ME2zMlQ1OjZ4IN88US=> NWPsXpBMW0GQR1XS
HCC2218 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnWzTWM2OD1|LkS2PVM4KM7:TR?= NWnXbXFKW0GQR1XS
MEG-01 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXwe4h[UUN3ME2zMlU6PjhizszN NETlc5FUSU6JRWK=
NB12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF35Rm9KSzVyPUOuOVk5QDhizszN M1\4[HNCVkeHUh?=
SNB75 NHHB[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwNkCxNFMh|ryP NFHpd21USU6JRWK=
KMS-12-PE MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176XWlEPTB;Mz62O|czOyEQvF2= NH\ZTopUSU6JRWK=
SKM-1 NF\Td|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNwN{GzO|Yh|ryP MoXnV2FPT0WU
COLO-320-HSR NHPuZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn4d5JKSzVyPUOuO|U3OzRizszN MXjTRW5ITVJ?
NKM-1 NVHGUGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj0bFhPUUN3ME2zMlc4Ozd6IN88US=> NV3NU|d4W0GQR1XS
TE-6 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTNwOUS1OlEh|ryP M1nYXHNCVkeHUh?=
D-336MG NEHJPWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfRPZpNUUN3ME20MlAyOTZ4IN88US=> MmqzV2FPT0WU
NCI-H1650 M1;iZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HCO2lEPTB;ND6xOVc6PyEQvF2= MlHBV2FPT0WU
ES3 NUHkNWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTkTWM2OD12LkOyPFI1KM7:TR?= MU\TRW5ITVJ?
YT M1j2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD12LkO1OFI1KM7:TR?= NIf4XGFUSU6JRWK=
ES5 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXhcI1KSzVyPUSuOFAzPTVizszN NFf2TIJUSU6JRWK=
LB647-SCLC M4WzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXNWhKSzVyPUSuOVY{ODhizszN NXTKfI9nW0GQR1XS
HAL-01 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTRwNUewN|Qh|ryP M2GyPHNCVkeHUh?=
LP-1 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwN{KzO|Eh|ryP NXrzSnp4W0GQR1XS
BC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTVwMEC0OFch|ryP M2T0PXNCVkeHUh?=
EB-3 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LpUWlEPTB;NT6wN|A1OSEQvF2= NUnWT2JLW0GQR1XS
GT3TKB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVTGlEPTB;NT6xO|Y3OiEQvF2= NVG2bnBVW0GQR1XS
NCI-H209 M2HFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\jWmlEPTB;NT6xPVM2OiEQvF2= M2\aRXNCVkeHUh?=
BT-474 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTVwMkOxNFIh|ryP NWfL[JM4W0GQR1XS
RKO MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTVwMkO0NlIh|ryP NHL2ZlRUSU6JRWK=
SIMA MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nEUGlEPTB;NT6zNFc3PSEQvF2= MnfMV2FPT0WU
RL Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DCTmlEPTB;NT6zO|U1OSEQvF2= MULTRW5ITVJ?
GCIY NHjIRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\qeVVKSzVyPUWuOFczOzZizszN MmPlV2FPT0WU
Calu-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm2eFlKSzVyPUWuOlIzKM7:TR?= NY\iW49NW0GQR1XS
ALL-PO NHK4c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwNkO3PVUh|ryP MVfTRW5ITVJ?
ARH-77 NYHPdFRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnQNJdRUUN3ME21MlY4ODh5IN88US=> M4P5VXNCVkeHUh?=
A4-Fuk NGrONHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2RmFOUUN3ME22MlA5OTF6IN88US=> MWrTRW5ITVJ?
NCI-H1581 NVLBTlRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfmbFNKSzVyPU[uNlM5PDlizszN MVPTRW5ITVJ?
HUTU-80 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jteGlEPTB;Nj6zOlg6PyEQvF2= Ml;vV2FPT0WU
TGW NE\HSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjsb2NbUUN3ME22MlQ2PTl|IN88US=> MWjTRW5ITVJ?
SK-N-FI NFzhZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnkclZ2UUN3ME22MlQ2QDV2IN88US=> MVfTRW5ITVJ?
U-266 M{m0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\PTWM2OD14LkWxPVI3KM7:TR?= NXi2VFNmW0GQR1XS
EM-2 M{Wycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yzOGlEPTB;Nj62O|A6QSEQvF2= MXzTRW5ITVJ?
NMC-G1 NHGwO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lrd2lEPTB;Nj63NVg6PSEQvF2= NIHuRZlUSU6JRWK=
KASUMI-1 NEHrOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTZwOES3PFch|ryP NGK2bVhUSU6JRWK=
NALM-6 M{PTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PPZWlEPTB;Nj64Olc2PCEQvF2= NVj1WWV3W0GQR1XS
OCI-AML2 NHqxdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonUTWM2OD15LkCwN|I3KM7:TR?= MVvTRW5ITVJ?
SHP-77 NX:1fo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnyeFB{UUN3ME23MlIzPDNizszN MoXKV2FPT0WU
NOMO-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTdwMkSyOVQh|ryP M4TK[3NCVkeHUh?=
SK-N-DZ NXqxU|BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS3[ZJKSzVyPUeuO|ExQDlizszN MlrLV2FPT0WU
LB1047-RCC Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXwTWM2OD15LkeyNlMyKM7:TR?= MWDTRW5ITVJ?
MZ1-PC Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTdwOE[1OVgh|ryP NYXn[mtjW0GQR1XS
NB10 M3;vV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITvboVKSzVyPUeuPVk2PTZizszN NEH6eGVUSU6JRWK=
RL95-2 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXDXWhpUUN3ME24MlExQDR{IN88US=> M{TTZnNCVkeHUh?=
OMC-1 MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT3cFdKSzVyPUiuOVIyQTFizszN MlHFV2FPT0WU
D-283MED MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3PTWM2OD16LkmxO|E6KM7:TR?= NIjKSlBUSU6JRWK=
MC116 M4fX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDyWZpwUUN3ME24Mlk4QTRizszN NEO2bm1USU6JRWK=
SJSA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjaTWM2OD17LkC5NFkyKM7:TR?= NEjudmNUSU6JRWK=
JiyoyeP-2003 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTlwMkmzNVch|ryP NGHGXYdUSU6JRWK=
IST-MEL1 NFzYPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;uXGZbUUN3ME25Mlc1OTl6IN88US=> NIXyNYlUSU6JRWK=
CTV-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\qXIxKSzVyPUGwMlA6PzlizszN MVPTRW5ITVJ?
NH-12 NFjUZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTZTWM2OD1zMD6yOFM{KM7:TR?= M2jIdXNCVkeHUh?=
CA46 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFyLkO2NUDPxE1? NYTGUJA3W0GQR1XS
NCI-SNU-1 NGLpRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;jTWM2OD1zMD60PVY6KM7:TR?= M17adXNCVkeHUh?=
SCLC-21H NYPwXW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFyLk[1PVYh|ryP NXPmUJF1W0GQR1XS
EC-GI-10 NX;t[VM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFyLkewN|Eh|ryP NX;5[3VyW0GQR1XS
SR Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPIS5VKSzVyPUGxMlAyQDVizszN NX;6XWpmW0GQR1XS
NCI-H1648 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjH[odKSzVyPUGxMlA6PjVizszN NX\BPI13W0GQR1XS
TGBC1TKB NUDiU3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITSSHJKSzVyPUGxMlQyODJizszN M3q0[3NCVkeHUh?=
EW-11 NGHIOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfRPW1KSzVyPUGxMlUyQDZizszN MYTTRW5ITVJ?
SK-MM-2 M4rTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjSPIJKSzVyPUGxMlgxPjFizszN NInISHVUSU6JRWK=
NCI-H524 NVvlW4JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mxPWlEPTB;MUGuPVgzOiEQvF2= MYLTRW5ITVJ?
NOS-1 NXftU2JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF{LkCzOFUh|ryP M1rLWnNCVkeHUh?=
AM-38 NYDL[GxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF{LkW2N|Mh|ryP NF\QTlhUSU6JRWK=
A498 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjwRZBKSzVyPUGyMlcxPjlizszN MoLvV2FPT0WU
KARPAS-422 NV3T[2psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HyeWlEPTB;MUKuO|Q6PiEQvF2= MoDJV2FPT0WU
LU-139 NXjo[4xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF{LkmwNlYh|ryP MoK2V2FPT0WU
COR-L88 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjwN5B3UUN3ME2xNk46Ozh{IN88US=> NYHIdJpSW0GQR1XS
K5 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX36bYRHUUN3ME2xNk46PDZ{IN88US=> MVXTRW5ITVJ?
NB13 NWrGOm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2SHBKSzVyPUGyMlk4QDNizszN MYXTRW5ITVJ?
MRK-nu-1 M3zqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zzUGlEPTB;MUOuNVk2KM7:TR?= MUXTRW5ITVJ?
MHH-NB-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m0WGlEPTB;MUOuNlkxOiEQvF2= NGrjbGxUSU6JRWK=
KU812 NXnXVYc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF|Lk[xNlQh|ryP NFTZdYdUSU6JRWK=
TE-12 M1fWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjyTWM2OD1zMz62PVk1KM7:TR?= NFTpPIRUSU6JRWK=
NCI-N87 NFzxcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe1T3FSUUN3ME2xN{44OzZizszN MVnTRW5ITVJ?
EB2 M1;ub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfGOodZUUN3ME2xN{45PTB3IN88US=> MkL5V2FPT0WU
DB NXfxOWRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF|Lkm4PFUh|ryP MVTTRW5ITVJ?
697 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPRZ4RjUUN3ME2xOE41PTFzIN88US=> NVHjOIZ[W0GQR1XS
MSTO-211H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF2Lke0OFgh|ryP NG\PVnJUSU6JRWK=
JVM-2 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF2Lke3N|Uh|ryP NWLy[|ZmW0GQR1XS
COLO-824 NX;rOoVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHX[Is6UUN3ME2xOE44QTl2IN88US=> NEnIOYdUSU6JRWK=
BC-3 NWLSPGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLzOFhKSzVyPUG1MlM6QCEQvF2= MYDTRW5ITVJ?
BOKU M3fWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmwTWM2OD1zNT65OlA5KM7:TR?= Ml74V2FPT0WU
GOTO MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonGTWM2OD1zNj65OlE4KM7:TR?= MUPTRW5ITVJ?
HCC2157 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LsXGlEPTB;MUeuOFc2PSEQvF2= MV\TRW5ITVJ?
LS-1034 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPy[XRRUUN3ME2xO{43QDF6IN88US=> Mke1V2FPT0WU
CAL-148 NGTKVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF5Lkm3PVYh|ryP MX7TRW5ITVJ?
MOLT-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF6LkiyNFgh|ryP M1nRN3NCVkeHUh?=
Daudi NYO0Wo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C3T2lEPTB;MUiuPVI{OSEQvF2= MknCV2FPT0WU
J-RT3-T3-5 NVO1XIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF7LkSwOlYh|ryP NXfEO|d7W0GQR1XS
KMOE-2 NHPrR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPxXHdEUUN3ME2xPU43PDh{IN88US=> M2P3b3NCVkeHUh?=
HL-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HmdmlEPTB;MkCuNVk3PSEQvF2= NEfQVZRUSU6JRWK=
P31-FUJ M3;BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHmSGx7UUN3ME2yNE41PzV|IN88US=> MX\TRW5ITVJ?
IM-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJyLk[yNlQh|ryP MkXTV2FPT0WU
HDLM-2 NEjNOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TYVWlEPTB;MkCuPFgzOSEQvF2= MVXTRW5ITVJ?
NCI-H1304 NFTRdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJzLkCzNVEh|ryP NVPyNYxNW0GQR1XS
NCI-H345 NVfWXIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJzLkC2OFMh|ryP M1naVnNCVkeHUh?=
RPMI-6666 M1K2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPQTWM2OD1{MT6zOlAzKM7:TR?= NXSyTXhDW0GQR1XS
GR-ST MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Psc2lEPTB;MkGuOFE4KM7:TR?= MXfTRW5ITVJ?
CHP-126 M{nGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnsTWM2OD1{MT62NVgyKM7:TR?= NIDpXllUSU6JRWK=
EHEB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PaNGlEPTB;MkGuOlc{OSEQvF2= NUW3Rll7W0GQR1XS
CPC-N NXj1SGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HGSWlEPTB;MkSuNFIxOSEQvF2= Mln3V2FPT0WU
NB1 NG\MdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PxUGlEPTB;MkSuOlk{QSEQvF2= MWjTRW5ITVJ?
LS-123 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ2LkmwNVIh|ryP Mn62V2FPT0WU
ST486 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fIOWlEPTB;MkWuNVEyOyEQvF2= MkC4V2FPT0WU
NCI-H1963 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX3ZZpKSzVyPUK2MlA3OjNizszN NIHzTFlUSU6JRWK=
U-87-MG NV24[opTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVfI9KSzVyPUK2Mlc3PDRizszN Mn\QV2FPT0WU
COR-L279 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHlcYdKSzVyPUK2Mlc6OjJizszN M4fOWXNCVkeHUh?=
LU-165 M1jjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ6LkC4OlEh|ryP M{nCXnNCVkeHUh?=
COLO-800 NX;aSnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfyeY5NUUN3ME2yPE4zQTV4IN88US=> NHu5[XpUSU6JRWK=
ETK-1 M2LGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTnTWM2OD1{OD6zOFQ3KM7:TR?= MXnTRW5ITVJ?
LNCaP-Clone-FGC Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUdHhKSzVyPUK5MlkzQDFizszN MmfEV2FPT0WU
SIG-M5 M1nT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PyPGlEPTB;M{CuO|k2OiEQvF2= M{LENnNCVkeHUh?=
NB6 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL4[3puUUN3ME2zNE46PTB|IN88US=> NXLPepdFW0GQR1XS
NCI-H2107 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYToPYtnUUN3ME2zNU4zOzN6IN88US=> NFfacGpUSU6JRWK=
SNU-C1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7aTWM2OD1|MT6zNVI3KM7:TR?= M3\wT3NCVkeHUh?=
JAR NGHtWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Bb2hlUUN3ME2zNU4{Pzl7IN88US=> M3nNPHNCVkeHUh?=
L-363 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTN{LkKxOFQh|ryP NXfUdmlXW0GQR1XS
EW-24 NIL2SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHkTWM2OD1|Mj6zOFc1KM7:TR?= MV3TRW5ITVJ?
NB69 NGf5fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDidlNKSzVyPUOzMlY1PTRizszN MVHTRW5ITVJ?
EW-13 NVnUVFRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XL[WlEPTB;M{OuPFk3QSEQvF2= NUnkR4M5W0GQR1XS
Ramos-2G6-4C10 NEXuOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjKTXZJUUN3ME2zOE4zQTl|IN88US=> MkD5V2FPT0WU
TE-11 NV3CTolMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrUU4pNUUN3ME2zOE41QDJ{IN88US=> MWLTRW5ITVJ?
L-428 M3H0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN2Lke1N|Yh|ryP MVvTRW5ITVJ?
KP-N-YN NEm3NnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjSOJZKSzVyPUO0MlkxPTdizszN M2\MbnNCVkeHUh?=
CGTH-W-1 NXnJNoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nXV2lEPTB;M{[uPVA1QCEQvF2= NUHydWpvW0GQR1XS
K-562 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1|Nz6wPFY1KM7:TR?= MXrTRW5ITVJ?
NCI-H1299 M1frdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTN6LkG2NFMh|ryP NWPofWIxW0GQR1XS
RCC10RGB NFnQbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L6bmlEPTB;M{iuNlA5OyEQvF2= NFPQco5USU6JRWK=
NCI-SNU-16 M4S2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTN6LkW2OVMh|ryP NIrGcGxUSU6JRWK=
LC-2-ad M3;0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfGTHZKSzVyPUO5MlQ{OzdizszN NEX4VnFUSU6JRWK=
MHH-PREB-1 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGiyV2pKSzVyPUO5Mlc{QDhizszN NHzUcnNUSU6JRWK=
NCI-H64 M3vId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fkTGlEPTB;NECuNFk1QCEQvF2= NFW5eZhUSU6JRWK=
LB996-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PERWlEPTB;NECuPFcyPiEQvF2= MUDTRW5ITVJ?
DEL NF7WN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXuTWM2OD12MT60OFA2KM7:TR?= MXHTRW5ITVJ?
MLMA NH\ZV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfa[lRKSzVyPUSxMlc2QTVizszN M3j5WnNCVkeHUh?=
SBC-1 NVm4WW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHdo5KSzVyPUSyMlE5ODZizszN NG\5dY1USU6JRWK=
MPP-89 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHlTWM2OD12Mj61PFc2KM7:TR?= MXLTRW5ITVJ?
MV-4-11 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fXemlEPTB;NEKuPVA3PyEQvF2= M4jhdnNCVkeHUh?=
EoL-1- MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fu[WlEPTB;NESuNVU3QCEQvF2= NUjoTnBbW0GQR1XS
CW-2 NVvuTlZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR2LkizOFIh|ryP MWLTRW5ITVJ?
HT M4jHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPfGlEPTB;NEWuO|AxPyEQvF2= NIH6WXFUSU6JRWK=
SW954 NUDpXHg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;CTWM2OD12Nz60NVI5KM7:TR?= MkfQV2FPT0WU
A3-KAW NG\yVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PjOGlEPTB;NEmuPFA3OSEQvF2= NGi1eZpUSU6JRWK=
TC-YIK MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i5bmlEPTB;NUCuNFM3OyEQvF2= MY\TRW5ITVJ?
SW962 NWS1R|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXlTWM2OD13ND64N|U4KM7:TR?= M2jybXNCVkeHUh?=
KP-N-RT-BM-1 NV7PSlRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13mRWlEPTB;NU[uOlY{QCEQvF2= NVXRVGVWW0GQR1XS
NCI-H1395 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XLSWlEPTB;NUiuPFE4OiEQvF2= NV3ldmlSW0GQR1XS
RPMI-8402 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X4VWlEPTB;NUiuPVUzPiEQvF2= MX3TRW5ITVJ?
SCH M3vWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZyLkm2N|gh|ryP MWDTRW5ITVJ?
NCI-H2196 NXe5c|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvVTWM2OD14MT6yN|Eh|ryP M3zMd3NCVkeHUh?=
LOXIMVI NYXCTINmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDvSJJKSzVyPU[xMlgzPjZizszN NWf6WWFLW0GQR1XS
TGBC24TKB MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TkZWlEPTB;NkKuNVQ6OSEQvF2= M2TEfnNCVkeHUh?=
SK-MEL-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK4eXhTUUN3ME22N{46QDl{IN88US=> M4DoRnNCVkeHUh?=
U-698-M NU\nTFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG0TWM2OD14OD61Olg4KM7:TR?= MXfTRW5ITVJ?
NCI-H1522 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTMTWM2OD14OT6wNFQ4KM7:TR?= NV\zW3hIW0GQR1XS
UACC-812 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW3XG9KSzVyPU[5MlUzODlizszN MVLTRW5ITVJ?
MHH-CALL-2 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWxSGx5UUN3ME23NE4xPiEQvF2= NYjmfYNmW0GQR1XS
NB5 M1rXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPJVJVKSzVyPUewMlM1PjhizszN M3XKW3NCVkeHUh?=
KARPAS-299 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3TWM2OD15MD60OFQ4KM7:TR?= MVjTRW5ITVJ?
NCI-H1694 NF7GfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTjTWM2OD15MT6wN|Ih|ryP MUPTRW5ITVJ?
NCI-H82 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLd|RKSzVyPUexMlk2ODdizszN NGLKWZlUSU6JRWK=
SCC-15 M4nxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\WPGlEPTB;N{KuN|Qh|ryP M{L4SHNCVkeHUh?=
NCI-H1436 NVnpdYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGwTWM2OD15Mj63OFU3KM7:TR?= NInnWnhUSU6JRWK=
ATN-1 M{\tT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\FTWM2OD15ND61NFUh|ryP NF;nSoFUSU6JRWK=
RPMI-8866 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTd2Lke1NFkh|ryP NHfOcHZUSU6JRWK=
HCC1599 NGSzclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTd2Lki3N|Ih|ryP MV\TRW5ITVJ?
NCI-H1155 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTd2LkmzOlch|ryP NYq0WXgyW0GQR1XS
DOHH-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLsfVVKSzVyPUe0Mlk2OTRizszN MWTTRW5ITVJ?
SK-NEP-1 NWfqdHk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\JTWM2OD15NT6wO|U1KM7:TR?= NIf0T4tUSU6JRWK=
HCC1187 NGnYWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXITWM2OD15Nz62NVIzKM7:TR?= M1nyfnNCVkeHUh?=
NCI-H322M NVHKVJRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTQOlBOUUN3ME23PE4{PzB7IN88US=> MWXTRW5ITVJ?
NCI-H526 NVvMVZdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDWIJKSzVyPUe4MlU5PzdizszN NFfNRZdUSU6JRWK=
NCI-H2171 NXjOUnBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPQTWM2OD15OT60NVM3KM7:TR?= M2XXO3NCVkeHUh?=
COLO-668 NHPLOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTDTWM2OD16MT61PFg1KM7:TR?= NIDBbIRUSU6JRWK=
RS4-11 NHn6S5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTh{LkK1NFUh|ryP NHfkSIZUSU6JRWK=
NCI-H716 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonxTWM2OD16Mj65NFc2KM7:TR?= MXPTRW5ITVJ?
LU-134-A MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH3eoNDUUN3ME24N{4yOzVzIN88US=> Ml\UV2FPT0WU
RPMI-8226 NIHscIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e1eGlEPTB;OESuNlExPyEQvF2= NXLHXpU3W0GQR1XS
KY821 NHHmboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTlzLk[1OVEh|ryP NX\QPG97W0GQR1XS
ECC4 NUD5e3ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LQb2lEPTB;OUOuPFI3QSEQvF2= NWDwWmJrW0GQR1XS
EW-3 NGj6XG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPWTWM2OD17ND65NFgyKM7:TR?= NIjoWHNUSU6JRWK=
NB7 M1jPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHaTWM2OD17NT63O|g3KM7:TR?= M4qzNXNCVkeHUh?=
NCI-H720 NFvzfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPXTWM2OD17OD60NFYyKM7:TR?= M{XRbXNCVkeHUh?=
NCI-H446 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nsWGlEPTB;OUmuO|U5QCEQvF2= MVzTRW5ITVJ?
NCI-H889 NIHtNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m4ZmlEPTB;MUC0MlI1OiEQvF2= MWjTRW5ITVJ?
EW-22 NWLWRYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNZ|JTUUN3ME2xNFYvOTlizszN MWrTRW5ITVJ?
BV-173 NXvmNWdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFyOD63Nlgh|ryP MmGxV2FPT0WU
WSU-NHL NXvpeHh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFyOT62O|Eh|ryP MoP0V2FPT0WU
MN-60 NIn3c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jqTmlEPTB;MUC5MlY6KM7:TR?= NFv0TWtUSU6JRWK=
DG-75 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\2UVRKSzVyPUGxN{4{PTJizszN NVzoSJNIW0GQR1XS
DMS-79 M3jITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX5VYE1UUN3ME2xNVcvOzh{IN88US=> MlzOV2FPT0WU
SK-MEL-1 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni1TWM2OD1zMUiuNFA6KM7:TR?= NHPoNIFUSU6JRWK=
DMS-153 NV7JbnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HnWWlEPTB;MUKxMlc1PSEQvF2= MlXWV2FPT0WU
NCI-H510A M3HSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInFR25KSzVyPUGyO{4{OiEQvF2= MX7TRW5ITVJ?
BE-13 NYmwZ2VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX1cmtGUUN3ME2xN|QvODR2IN88US=> M1T3XnNCVkeHUh?=
KP-N-YS M3vzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjqTlNKSzVyPUGzPU44OzZizszN NGrufm9USU6JRWK=
SUP-T1 NUnhZmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jwXWlEPTB;MUSzMlcxQCEQvF2= MXrTRW5ITVJ?
EW-12 NH76OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljhTWM2OD1zNESuOlk6KM7:TR?= NYS0WlF{W0GQR1XS
NB14 NXX5[IVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLTeZlKSzVyPUG0O{4xQDJizszN MmDjV2FPT0WU
MDA-MB-134-VI M3\neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEntSpRKSzVyPUG0PE4zPjhizszN NIL2VIlUSU6JRWK=
NCI-H1770 NH7hcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLtTWM2OD1zNU[uNlc6KM7:TR?= MnSzV2FPT0WU
TUR NHPCd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXCTGRKSzVyPUG2O{45PyEQvF2= NVHNPJd2W0GQR1XS
NCI-H1417 NEn0VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jlbmlEPTB;MUiwMlM{OSEQvF2= M2\XZXNCVkeHUh?=
IMR-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr0ZXhbUUN3ME2xPFEvPTdzIN88US=> NH\5S3hUSU6JRWK=
NCI-H226 M13DSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoSxTWM2OD1zOEiuPFY3KM7:TR?= Ml\ZV2FPT0WU
NCI-H187 NGLtUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHURZBVUUN3ME2xPVAvODZ2IN88US=> NFf6O3dUSU6JRWK=
SF539 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG0c25yUUN3ME2xPVIvPzJ6IN88US=> M{iz[nNCVkeHUh?=
TALL-1 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF7OD6zNFQh|ryP NH\KcJVUSU6JRWK=
TE-441-T NWHOfJhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP2TngzUUN3ME2xPVkvPzN7IN88US=> MlP6V2FPT0WU
REH NFPPcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHewZ|hKSzVyPUKzOk43OjZizszN M2e2NXNCVkeHUh?=
MS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ|OT6xNlEh|ryP MlyzV2FPT0WU
THP-1 M2n6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ4ND63N|gh|ryP NXLFd5NsW0GQR1XS
NCI-H1838 M{T4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljBTWM2OD1{N{GuOFU3KM7:TR?= NXjObYxSW0GQR1XS
P30-OHK M{XXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DPbmlEPTB;MkizMlg1PyEQvF2= NXnPfFI1W0GQR1XS
C8166 NH7QO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDSTWM2OD1|NEWuN|M5KM7:TR?= NISyVZFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID